Resistin May Be Potential Biomarker For Disease Severity In Patients With Psoriasis, Study Suggests

HCPlive (3/31, Smith) reports, “Psoriasis is potentially associated with metabolic disorders, new findings suggest, and resistin may provide a biomarker for disease severity.” Researchers “noted that an increase in markers can suggest inflammatory processes among patients that point to the risk of conditions accompanying psoriatic disease.” The study found “that children with psoriasis were shown to have higher serum levels of resistin, homocysteine, leptin, and pentraxin 3.” They concluded that in the “study, the levels of the analyzed biomarkers in” patients with psoriasis “were not related to body weight, which implies that psoriasis without accompanying obesity may be an independent risk factor for systemic inflammation.” However, they said, “resistin, in particular, appeared to be a potential marker of psoriasis severity, which could be used for monitoring disease progression. However, this relationship requires further investigation.” The study was published in the Journal of Clinical Medicine.